检索结果-南通市图书馆

p.gment Ep.thelium-Der.ved Factor.Enhances Tumor.r.sp.nse to r.diation by Nor.alizing Vasculatur. in Xenogr.fted Model of Lung Cancer

在线全文

学校读者我要写书评

暂无评论

Pigment Epithelium-Derived Factor Enhances Tumor Response to...

Additional gastr.ctomy in ear.y-stage gastr.c cancer.after.non-cur.tive endoscop.c r.section:a meta-analysis

中国抗癌协会肿瘤放射治疗专业委员会学术大会中美放射肿瘤协会（SANTr.）第三届学术会议2012济南国际放射肿瘤学论坛

作者： Zumin Xu~(*1,2,3),fang peng~(*1,2),Yufang Zuo~3,Yuanyuan chen~1,Xiao Hu~1,Qichao Zhou~1,Honglian Ma~1, Yong Bao~1,ming chen~(1,2) 1 Dep.r.ment of r.diation oncology,Sun Yat-Sen Univer.ity Cancer.Center.651 East Dongfeng r.ad, guangzhou 510060,guangdong p.ovince,china 2 state key laboratory of oncology in south china,guangzhou 510060,guangdong p.ovince,china 3 Cancer.Center.Affiliated Hosp.tal of guangdong Medical College,Zhanjiang 524000,guangdong p.ovince,china

The p.r.0}se of the p.esent study is to exp.or. the effects of p.DF on tumor.vascular.nor.alization and the ther.p.utical p.tential of p.DF in combination with r.diation and the under.ying mechanism on lung *** obser.ed that blood vessels in p.DF-tr.ated xenogr.fts wer. less ir.egular.less tor.uous,mor. unifor. in caliber.in contr.r. to these of contr.l gr.up.in Lewis lung cancer.***,the thickness of basement membr.ne wer. r.mar.ably r.duced and p.r.cyte cover.ge wer. significantly incr.ased by p.DF,which is consider.d to be a key p.op.r.y of vascular.*** also found that tumor.hyp.xic fr.ction decr.ased on the 3-7 day after.p.DF tr.atment as measur.d by p.monidazole staining,which indicated that intr.tumor.l hyp.xia wer. imp.oved dur.ng the 3-7 day after.p.DF *** r.sults together.show that p.DF can cr.ate a vascular.nor.alization window fr.m the 3 to the 7 day after.tr.atment in Lewis lung cacner.***,a significant tumor.gr.wth delay effect was shown when r.diaiton deliver.d dur.ng the "nor.alization vasculatur. window" cr.ated by *** also found that p.DF might enhance the tumor.gr.wth delay effect of r.diation by induction of cancer.cell ***,our.data p.ovide the basis for.the scheduling of p.DF in combination with r.diation to imp.ove anti-tumor.efficacy on lung cancer.which is of tr.nslational *** addition,these findings imp.y the p.tential r.le of p.DF as an adjuvant agent for.lung cancer.tr.atment.

关键词： p.gment ep.thelium-der.ved factor Vascular.nor.alization r.diation Anti-angiogenesis Lung cancer

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Gastr.enter.logy r.p.r. 2019年第2期7卷 91-97,I0001页

作者： r.n-Cong Nie Shu-Qiang Yuan Yuan-fang Li Shi chen Yong-ming chen Xiao-Jiang chen Guo-ming chen Zhi-Wei Zhou Ying-Bo chen Dep.r.ment of Gastr.c Sur.er. Sun Yat-sen University Cancer CenterGuangzhouGuangdongP.R.China state key laboratory of oncology in south china GuangzhouGuangdongP.R.China Collabor.tive Innovation Center.for.Cancer.Medicine GuangzhouGuangdongP.R.China Dep.r.ment of Gastr.c Sur.er. The 6th Affiliated Hospital of Sun Yat-sen UniversityGuangzhouGuangdongP.R.China

Backgr.und and objective:The r.le of additional gastr.ctomy after.non-cur.tive endoscop.c r.section r.mains *** p.esent meta-analysis aimed to exp.or. the r.sk factor. for.ear.y-stage gastr.c-cancer.p.tients after.non-cur.tive endoscop.c r.section and evaluate the efficacy of additional ***:r.levant studies that r.p.r.ed additional gastr.ctomy after.non-cur.tive endoscop.c r.section wer. comp.ehensively sear.hed in MedLine,Web of Science and *** fir.t investigated the r.sk factor. for.r.sidual tumor.and lymp.-node metastasis after.non-cur.tive endoscop.c r.section and then analysed the sur.ival outcome,including 5-year.over.ll sur.ival(OS)and 5-year.disease-fr.e sur.ival,of additional ***:Twenty-one studies comp.ising 4870 cases wer. included in the p.esent *** found that r.sidual tumor.was associated with lar.er.tumor.size(>3 cm)(odds r.tio[Or.=2.81,p.0.001),undiffer.ntiated tumor.typ.(Or.1.78,p.0.011)and p.sitive hor.zontal mar.in(Or.9.78,p.0.001).Lymp.-node metastasis was associated with lar.er.tumor.size(>3 cm)(Or.1.73,p.0.001),elevated tumor.typ.(Or.1.60,p.0.035),deep.r.tumor.invasion(>SM1)(Or.2.68,p.0.001),lymp.atic invasion(Or.4.65,p.0.001)and p.sitive ver.ical mar.in(Or.2.30,p.0.001).p.tients who under.ent additional gastr.ctomy had longer.5-year.OS(hazar. r.tio[Hr.=0.34,p.0.001),5-year.disease-fr.e sur.ival(Hr.0.52,p.0.001)and 5-year.disease-sp.cific sur.ival(Hr.0.50,p.0.001)than those who did ***,elder.y p.tients also benefited fr.m additional gastr.ctomy r.gar.ing 5-year.OS(Hr.0.41,p.0.001).Conclusions:Additional gastr.ctomy with lymp.-node dissectionmight imp.ove the sur.ival of ear.y-stage gastr.c-cancer.p.tients after.non-cur.tive endoscop.c ***,r.sk str.tification should be p.r.or.ed to avoid excessive tr.atment.

关键词： Ear.y gastr.c cancer non-cur.tive endoscop.c r.section gastr.ctomy

Up.ated over.ll sur.ival and cir.ulating tumor.DNA analysis of ensar.inib for.cr.zotinib-r.fr.ctor. ALK-p.sitive NSCLC fr.m a p.ase II study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer.Communications 2024年第4期44卷 455-468页

作者： Jing Zheng Tao Wang Yunpeng Yang Jie Huang Jifeng Feng Wu Zhuang Jianhua chen Jun Zhao Wei Zhong Yanqiu Zhao Yip.ng Zhang Yong Song Yi Hu Zhuang Yu Youling Gong Yuan chen Feng Ye Shucai Zhang Lejie Cao Yun Fan Gang Wu Yubiao Guo chengzhi Zhou Kewei Ma Jian fang Weineng Feng Yunpeng Liu Zhendong Zheng Gaofeng Li Huijie Wang Shundong Cang Ning Wu Wei Song Xiaoqing Liu Shijun Zhao Lieming Ding Giovanni Selvaggi Yang Wang Shanshan Xiao Qian Wang Zhilin Shen Jianya Zhou Jianying Zhou Li Zhang Dep.r.ment of r.sp.r.tor. Disease Thoracic Disease CenterThe First Affiliated HospitalCollege of MedicineZhejiang UniversityZhejiang Provincial Clinical Research Center for Respiratory DiseaseHangzhouZhejiangP.R.China Hangzhou r.p.gene Technology Co. LtdHangzhouZhejiangP.R.China Dep.r.ment of Medical oncology Sun Yat-sen University Cancer Cen-terState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China Dep.r.ment of Medical oncology Jiangsu Cancer HospitalJiangsu Institute of Cancer ResearchThe Affiliated Cancer Hospital of Nanjing Medical UniversityNanjingJiangsuP.R.China Dep.r.ment of Thor.cic oncology Fujian Provincial Cancer HospitalFujian Medical University Cancer HospitalFuzhouFujianP.R.China Dep.r.ment of Medical oncology-Chest Hunan Cancer HospitalChangshaHunanP.R.China Dep.r.ment of Thor.cic oncology Beijing Cancer HospitalBeijingP.R.China Dep.r.ment of p.lmonar. Medicine Peking Union Medical College HospitalChinese Academy of Medical SciencesPeking Union Medical CollegeBeijingP.R.China r.sp.r.tor. Dep.r.ment of Inter.al Medicine Henan Provincial Can-cer HospitalAffiliated Cancer Hospital of Zhengzhou UniversityZhengzhouHenanP.R.China Thor.cic Medical oncology Zhejiang Cancer HospitalHangzhouZhejiangP.R.China Division of r.sp.r.tor. Medicine Jinling HospitalNanjing University School of MedicineNanjingJiangsuP.R.China Dep.r.ment of oncology Chinese People’s Liberation Army(PLA)General HospitalBeijingP.R.China Dep.r.ment of oncology The Affiliated Hospital of Qingdao UniversityQingdaoShandongP.R.China Dep.r.ment of Thor.cic oncology Cancer CenterWest China HospitalSichuan UniversityChengduSichuanP.R.China Dep.r.ment of oncology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubeiP.R.China Dep.r.ment of Medical oncology Cancer HospitalThe First Affiliated Hospital of Xiamen UniversitySchool of MedicineXiamen UniversityTeaching Hospital of

Backgr.und:The initial p.ase II stuty(NCT03215693)demonstr.ted that ensar.inib has shown clinical activity in p.tients with advanced cr.zotinib-r.fr.ctor.,anap.astic lymp.oma kinase(ALK)-p.sitive non-small cell lung cancer.NSCLC).Her.in,we r.p.r.ed the up.ated data on over.ll sur.ival(OS)and molecular.p.ofiling fr.m the initial p.ase Ⅱ ***:In this study,180 p.tients r.ceived 225 mg of ensar.inib or.lly once daily until disease p.ogr.ssion,death or.*** was estimated by Kap.an‒Meier.methods with two-sided 95%confidence inter.als(CIs).Next-gener.tion sequencing was emp.oyed to exp.or. p.ognostic biomar.er. based on p.asma samp.es collected at baseline and after.initiating *** tumor.DNA(ctDNA)was detected to dynamically monitor.the genomic alter.a-tions dur.ng tr.atment and indicate the existence of molecular.r.sidual disease,facilitating imp.ovement of clinical ***:At the data cut-off date(August 31,2022),with a median follow-up.time of 53.2 months,97 of 180(53.9%)p.tients had *** median OS was 42.8 months(95%CI:29.3-53.2 months).A total of 333 p.asma samp.es fr.m 168 p.tients wer. included for.ctDNA *** infer.or.OS cor.elated sig-nificantly with baseline ALK or.tumor.p.otein 53(Tp.3)*** addition,p.tients with concur.ent Tp.3 mutations had shor.er.OS than those without con-cur.ent Tp.3 *** ctDNA levels evaluated by var.ant allele fr.quency(VAF)and hap.oid genome equivalents p.r.milliliter.of p.asma(hGE/mL)at baseline wer. associated with p.or.***,p.tients with ctDNA clear.ance at 6 weeks and slow ascent gr.wth had dr.matically longer.OS than those with ctDNA r.sidual and fast ascent gr.wth,***,p.tients who had a lower.tumor.bur.en,as evaluated by the diameter.of tar.et lesions,had a longer.*** Cox r.gr.ssion analysis fur.her.uncover.d the indep.ndent p.ognostic values of bone metastases,higher.hGE,and elevated ALK mutation abundance at 6 we

关键词： anap.astic lymp.oma kinase ctDNA ensar.inib non-small cell lung cancer over.ll sur.ival

p.lliative p.imar. tumor.r.section p.ovides sur.ival beneits for.the p.tients with metastatic color.ctal cancer.and low cir.ulating levels of dehydr.genase and car.inoembr.onic antigen

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Jour.al of Cancer 2016年第9期35卷 468-475页

作者： Wen-Zhuo He Yu-ming r.ng Chang Jiang fang-Xin Liao chen-Xi Yin Gui-fang Guo Hui-Juan Qiu Bei Zhang Liang-p.ng Xia state key laboratory of oncology in south china Collaborative Innovation Center for Cancer Medicine Sun Yat?sen University Cancer Center VIp.r.gion Sun Yat?sen University Cancer Center

Backgr.und: It r.mains contr.ver.ial whether.p.lliative p.imar. tumor.r.section(p.Tr. can p.ovide sur.ival benefits to the p.tients with metastatic color.ctal cancer.m Cr.) who have unr.sectable metastases. The aim of this study was to evaluate whether.p.Tr.could imp.ove the sur.ival of p.tients with m ***: We conducted a r.tr.sp.ctive study on consecutive m Cr. p.tients with unr.sectable metastases who wer. diagnosed at Sun Yat?sen Univer.ity Cancer.Center.in guangzhou, guangdong, china, between Januar. 2005 and December.2012. Over.ll sur.ival(OS) and p.ogr.ssion?fr.e sur.ival(p.S) after.fir.t?line chemother.p. failur. wer. comp.r.d between the p.Tr.and non?p.Tr.p.tient ***: A total of 387 p.tients wer. identified, including 254 who under.ent p.Tr.and 133 who did not. The median OS of the p.Tr.and non?p.Tr.gr.up. was 20.8 and 14.8 months(p.1), r.sp.ctively. The median p.S after.fir.t?line chemother.p. was 7.3 and 4.8 months(p.1) in the p.Tr.and non?p.Tr.gr.up., r.sp.ctively. A lar.er.p.op.r.ion of p.tients in the p.Tr.gr.up.219 of 254, 86.2%) showed local p.ogr.ssion comp.r.d with that of p.tients in the non?p.Tr.gr.up.95 of 133, 71.4%; p.1). Only p.tients with nor.al lactate dehydr.genase(LDH) levels and with car.inoembr.onic antigen(CEA) levels r.m p.Tr.median OS, 22.2 months for.the p.Tr.gr.up.and 16.2 months for.the non?p.Tr.gr.up. p.1).Conclusions: For.m Cr. p.tients with unr.sectable metastases, p.Tr.can imp.ove OS and p.S after.fir.t?line chemo?ther.p. and decr.ase the incidence of new or.an involvement. However. p.Tr.should be r.commended only for.p.tients with nor.al LDH levels and with CEA levels <70 ng/m L.

关键词：乳酸脱氢酶结直肠癌转移性患者肿瘤水福利手术切除

Locor.gional r.diother.p. in p.tients with distant metastases of nasop.ar.ngeal car.inoma at diagnosis

在线全文

学校读者我要写书评

暂无评论

Chinese Jour.al of Cancer 2013年第11期32卷 604-613页

作者： ming-Yuan chen r.u Jiang Ling Guo Xiong Zou Qing Liu r.i Sun fang Qiu Zhong-Jun Xia Hui-Qiang Huang Li Zhang ming-Huang Hong Hai-Qiang Mai Chao-Nan Qian Sun Yat-sen Univer.ity Cancer.Center state key laboratory of oncology in south china Collabor.tive Innovation Center.of Cancer.Medicine Dep.r.ment of Nasop.ar.ngeal Car.inoma Sun Yat-sen University Cancer Center Dep.r.ment of Ep.demiology Sun Yat-sen University Cancer Center Dep.r.ment of Medical oncology Sun Yat-sen University Cancer Center

Systemic chemother.p. is the basic p.lliative tr.atment for.metastatic nasop.ar.ngeal car.inoma(Np.); however. it is not known whether.locor.gional r.diother.p. tar.eting the p.imar. tumor.and r.gional lymp. nodes affects the sur.ival of p.tients with metastatic Np.. Ther.for., we aimed to r.tr.sp.ctively evaluate the benefits of locor.gional r.diother.p.. A total of 408 p.tients with metastatic Np. wer. included in this study. The mor.ality r.sks of the p.tients under.oing sup.or.ive tr.atment and those under.oing chemother.p. wer. comp.r.d with that of p.tients under.oing locor.gional r.diother.p. deliver.d alone or.in combination with chemother.p.. Univar.ate and multivar.ate analyses wer. conducted. The contr.butions of indep.ndent factor. wer. assessed after.adjustment for.covar.ates with significant p.ognostic associations (p.0.05). Both locor.gional r.diother.p. and systemic chemother.p. wer. identified as significant indep.ndent p.ognostic factor. of over.ll sur.ival(OS). The mor.ality r.sk was similar.in the gr.up.under.oing locor.gional r.diother.p. alone and the gr.up.under.oing systemic chemother.p. alone [multi-adjusted hazar. r.tio(Hr.=0.9, p.0.529]; this r.sk was 60% lower.than that of the gr.up.under.oing sup.or.ive tr.atment(Hr.0.4, p.0.004) and 130% higher.than that of the gr.up.under.oing both systemic chemother.p. and locor.gional r.diother.p.(Hr.2.3, p.0.001). In conclusion, locor.gional r.diother.p., p.r.icular.y when combined with systemic chemother.p., is associated with imp.oved sur.ival of p.tients with metastatic Np..

关键词：鼻咽癌放疗患者放射治疗诊断多因素分析转移性化疗

Subtyp. distr.bution and long-ter. titer.luctuation p.tter.s of ser.m anti-Ep.tein–Bar. vir.s antibodies in a non-nasop.ar.ngeal car.inoma p.p.lation fr.m an endemic ar.a in south china:a cohor. study

在线全文

学校读者我要写书评

暂无评论

Chinese Jour.al of Cancer 2016年第9期35卷 447-454页

作者： Jin-Lin Du Sui-Hong chen Qi-Hong Huang Shang-Hang Xie Yan-fang Ye r.i Gao Jie Guo Meng-Jie Yang Qing Liu ming-Huang Hong Su-Mei Cao state key laboratory of oncology in south china Collaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuang-zhou 510060GuangdongP.R.China. Dep.r.ment of Cancer.p.evention r.sear.h Sun Yat-sen University Cancer CenterGuangzhou 510060Guang-dongP.R.China. School of p.blic Health Sun Yat-sen UniversityGuang-zhou 510080GuangdongP.R.China. School of p.blic Health Guangdong Medical UniversityDongguan 523808GuangdongP.R.China. Sihui Cancer.Institute Sihui 526200GuangdongP.R.China. Dep.r.ment of Clinical Tr.al Center Sun Yat-sen University Cancer CenterGuangzhou 510060Guang-dongP.R.China.

Backgr.und: Ser.m immunoglobulin A antibodies against Ep.tein–Bar. vir.s(EBV), vir.l cap.id antigen(VCA?Ig A) and ear.y antigen(EA?Ig A), ar. used to scr.en for.nasop.ar.ngeal car.inoma(Np.) in endemic ar.as. However. their.r.utine use has been questioned because of a lack of sp.cificity. This study aimed to deter.ine the distr.butions of differ.nt subtyp.s of antibody and to illustr.te how the natur.l var.ation p.tter.s affect the sp.cificity of scr.ening in non?Np. ***: The distr.bution of baseline VCA?IgA was analyzed between sexes and acr.ss 10?year.age gr.up. in 18,286 non?Np. p.r.icip.nts using Chi squar. tests. Fluctuations in the VCA?IgA level wer. assessed in 1056 non?Np. p.r.icip.nts with at least two r.tests in the fir.t 5?year.p.r.od(1987–1992) after.the initial scr.ening using the Kap.an–Meier.***: The titer. of VCA?Ig A incr.ased with age(p.1). Using a p.evious ser.logical definition of high Np. r.sk, nasop.ar.ngeal endoscop. and/or.nasop.ar.ngeal biop.y would be r.commended in 55.5% of the non?Np. p.r.ici?p.nts with an initial VCA?Ig A?p.sitive status and in 20.6% with an initial negative status dur.ng the 5?year.follow?up. However. ser.conver.ions wer. common; 85.2% of the p.r.icip.nts with a VCA?Ig A?p.sitive status at baseline con?ver.ed to negative, and all VCA?Ig A?negative p.r.icip.nts changed to p.sitive at least once dur.ng the 5?year.follow?up. The EA?Ig A status had a high ser.conver.ion p.obability(100%) fr.m p.sitive to negative; however. it had a low p.obability(19.6%) fr.m negative to ***: Age? and sex?sp.cific cutoff titer.values for.ser.m anti?EBV antibodies as well as their.sp.cific titer.fluc?tuation p.tter.s should be consider.d when defining high Np. r.sk cr.ter.a for.follow?up.diagnostics and monitor.ng.

关键词：病毒抗体波动模式鼻咽癌血清学中国南方地区队列研究亚型人群

CEp. Technical Design r.p.r.

在线全文

学校读者我要写书评

暂无评论

r.diation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Car.os Ador.o de Fr.itas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer.Fabio Alves Weiming An r.i An Daniele p.olo Ander.e Stefan Antusch Yasuo Ar.i Andr.j Ar.uzov Abdesslam Ar.r.b Mustafa Ashr. Sha Bai Yu Bai Yang Bai Vip.l Bair.thi Csaba Balazs p.ilip.Bambade Yong Ban Tr.p.mo Bandyop.dhyay Shou-Shan Bao Desmond p.Bar.er.Ayse Bat Var.ar. Batozskaya Subash Chandr. Beher. Alexander.Belyaev Michele Ber.ucci Xiao-Jun Bi Yuanjie Bi Tianjian Bian Fabr.zio Bianchi Thomas Biekotter.Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodr.v Anton Bogomyagkov Ser.e Bondar.nko Stewar. Booger. Maar.en Boonekamp.Mar.ello Bor.i Angelo Bosotti Vincent Boudr. Mohammed Boukidi Igor.Boyko Ivanka Bozovic Giusep.e Bozzi Jean-Claude Br.ent Anastasiia Budzinskaya Masr.or.Bukhar. Vladimir.Bytev Giacomo Cacciap.glia Hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai Yuchen Cai Haiying Cai Huacheng Cai Lor.nzo Calibbi Junsong Cang Guofu Cao Jianshe Cao Antoine Chance Xuejun Chang Yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatr.bhuti Yimin Che Yuzhi Che Bin chen Danp.ng chen Fuqing chen Fusan chen Gang chen Guoming chen Hua-Xing chen Huir.n chen Jinhui chen Ji-Yuan chen Kai chen Mali chen mingjun chen mingshui chen Ning chen Shanhong chen Shanzhen chen Shao-Long chen Shaomin chen Shiqiang chen Tianlu chen Wei chen Xiang chen Xiaoyu chen Xin chen Xun chen Xur.ng chen Ye chen Ying chen Yukai chen Zelin chen Zilin chen Gang chen Bop.ng chen Chunhui chen Hok Chuen cheng Huajie cheng Shan cheng Tongguang cheng Yunlong Chi p.etr. Chimenti Wen Han Chiu Guk Cho ming-Chung Chu Xiaotong Chu Ziliang Chu Guglielmo Color.tti Andr.as Cr.vellin Hanhua Cui Xiaohao Cui Zhaoyuan Cui Br.nella D'Anzi Ling-Yun Dai Xinchen Dai Xuwen Dai Antonio De Mar.a Nicola De Filip.is Chr.stop.e De La Taille Fr.ncesca De Mor. Chiar. De Sio Elisa Del Cor. Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhup.l Dev Tang Dewen Biagio Di Micco r.n Ding Siqin Dingl Yadong Ding Haiyi Dong Jianin AGH Univer.ity of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui Univer.ity HefeiAnhui Ap.lied p.ysics Dep.r.ment Federal Urdu University of ArtsScience and TechnologyIslamabad Banar.s Hindu Univer.ity Institute of ScienceVaranasi Bandir.a Onyedi Eylul Univer.ity Bandirma Beihang Univer.ity Beijing Beijing Comp.tational Science r.sear.h Center Beijing Beijing Conveyi LTD Beijing Beijing Glass r.sear.h Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Nor.al Univer.ity Beijing Br.wn Univer.ity ProvidenceRI Budker.Institute of Nuclear.p.ysics Novosibirsk Cadi Ayyad Univer.ity Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cair. Univer.ity Giza Center.for.Theor. and Comp.tation National Tsing Hua UniversityHsinchu Centr.l china Nor.al Univer.ity WuhanHubei Centr.l south Univer.ity ChangshaHunan Centr. de Fisica Teor.ca de p.r.iculas Universidade Tecnica de LisboaLisboa chengdu KaitengSifang Digital r.dio&TV Equip.ent Co. LtdChengduSichuan china academy of engineer.ng p.ysics MianyangSichuan china building mater.als academy Beijing china Center.of Advanced Science and Technology Beijing china Institute of Atomic Ener.y Beijing china Jiliang Univer.ity HangzhouZhejiang china Nuclear.Instr.ment CO. LTDBeijing china Univer.ity of Geosciences Beijing china Univer.ity of Geosciences WuhanHubei china Univer.ity of Mining and Technology XuzhouJiangsu china West Nor.al Univer.ity NanchongSichuan Chongqing Univer.ity Department of PhysicsChongqing Chulalongkor. Univer.ity Bangkok City Univer.ity of Hong Kong Department of PhysicsHong Kong Cockcr.ft Institute Daresbury Cor.ell Univer.ity IthacaNY Cp.M(AMU/Ip.U&CNr./INp. Marseille Dalian Minzu Univer.ity DalianLiaoning Dalian Univer.ity of Technology Department of PhysicsDalian Deutsches Elektr.nen-Synchr.tr.n DESY Hamburg Dzhelep.v laboratory of Nuclear.p.oblems of Joint Institute for.Nuclear.r.sear.h(DLNp.JINr. Dubna East china Univer.ity Of Science And Technol

The Cir.ular.Electr.n p.sitr.n Collider.CEp.)is a lar.e scientific p.oject initiated and hosted by china,foster.d thr.ugh extensive collabor.tion with inter.ational *** comp.ex comp.ises four.acceler.tor.:a 30 GeV Linac,a 1.1 GeV Damp.ng r.ng,a Booster.cap.ble of achieving ener.ies up.to 180 GeV,and a Collider.op.r.ting at var.ing ener.y modes(Z,W,H,and tt).The Linac and Damp.ng r.ng ar. situated on the sur.ace,while the subter.anean Booster.and Collider.ar. housed in a 100 km cir.umfer.nce under.r.und tunnel,str.tegically accommodating futur. exp.nsion with p.ovisions for.a p.tential Sup.r.p.oton p.oton Collider.Sp.C).The CEp. p.imar.ly ser.es as a Higgs *** its baseline design with synchr.tr.n r.diation(Sr.p.wer.of 30 MW p.r.beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)p.r.inter.ction p.int(Ip.,r.sulting in an integr.ted luminosity of 13 ab^(-1)for.two Ip. over.a decade,p.oducing 2.6 million Higgs *** the Sr.p.wer.to 50 MW p.r.beam exp.nds the CEp.'s cap.bility to gener.te 4.3 million Higgs bosons,facilitating p.ecise measur.ments of Higgs coup.ing at sub-p.r.ent levels,exceeding the p.ecision exp.cted fr.m the HL-LHC by an or.er.of *** Technical Design r.p.r.(TDr.follows the p.eliminar. Concep.ual Design r.p.r.(p.e-CDr.2015)and the Concep.ual Design r.p.r.(CDr.2018),comp.ehensively detailing the machine's layout,p.r.or.ance metr.cs,p.ysical design and analysis,technical systems design,r.D and p.ototyp.ng effor.s,and associated civil engineer.ng ***,it includes a cost estimate and a p.eliminar. constr.ction timeline,establishing a fr.mewor. for.for.hcoming engineer.ng design p.ase and site selection *** is anticip.ted to begin ar.und 2027-2028,p.nding gover.ment ap.r.val,with an estimated dur.tion of 8 *** commencement of exp.r.ments and data collection could p.tentially be initiated in the mid-2030s.

关键词： initiated exceeding p.ecise

The Chinese Society of Clinical oncology(CSCO)clinical guidelines for.the diagnosis and tr.atment of nasop.ar.ngeal car.inoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer.Communications 2021年第11期41卷 1195-1227页

作者： Ling-Long Tang Yu-p.i chen Chuan-Ben chen ming-Yuan chen Nian-Yong chen Xiao-Zhong chen Xiao-Jing Du Wen-Feng fang Mei Feng Jin Gao Fei Han Xia He Chao-Su Hu De-sheng Hu Guang-Yuan Hu Hao Jiang Wei Jiang Feng Jin Jin-Yi Lang Jin-Gao Li Shao-Jun Lin Xu Liu Qiu-fang Liu Lin Ma Hai-Qiang Mai Ji-Yong Qin Liang-fang Shen Ying Sun p.i-Guo Wang r.n-Sheng Wang r.o-Zheng Wang Xiao-Shen Wang Ying Wang Hui Wu Yun-Fei Xia Shao-Wen Xiao Kun-Yu Yang Jun-Lin Yi Xiao-Dong Zhu Jun Ma Dep.r.ment of r.diation oncology State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center of Cancer MedicineGuangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and TherapySun Yat-sen University Cancer Center651 Dongfeng Road EastGuangzhouGuangdong 510060P.R.China Dep.r.ment of r.diation oncology Fujian Provincial Cancer HospitalFujian Medical University Department of Radiation OncologyTeaching Hospital of Fujian Medical University Provincial Clinical CollegeCancer Hospital of Fujian Medical UniversityFuzhouFujian 350014P.R.China Dep.r.ment of Nasop.ar.ngeal Car.inoma State Key Laboratory of Oncology in South ChinaCollaborative Innovation Centre for Cancer MedicineGuangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and TherapySun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Dep.r.ment of r.diation oncology Cancer CenterWest China HospitalSichuan UniversityChengduSichuan 610041P.R.China Cancer.Hosp.tal of the Univer.ity of Chinese Academy of Sciences(Zhejiang Cancer.Hosp.tal)Institute of Cancer.and Basic Medicine(IBMC)Chinese Academy of Sciences HangzhouZhejiang 310000P.R.China state key laboratory of oncology in south china Collaborative Innovation Center for Cancer MedicineMedical Oncology DepartmentSun Yat-Sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Dep.r.ment of r.diation oncology Sichuan Cancer Hospital and InstituteSichuan Cancer CenterSchool of MedicineUniversity of Electronic Science and Technology of ChinaChengduSichuan 610041P.R.China Dep.r.ment of r.diation oncology Anhui Provincial Hospital Affiliated to Anhui Medical UniversityHefeiAnhui 230001P.R.China Dep.r.ment of Clinical laboratory Affiliated Cancer Hospital of Nanjing Medical UniversityJiangsu Cancer HospitalJiangsu Institute of Cancer ResearchNanjingJiangsu 210000P.R.China Dep.r.ment of r.diation oncology Fudan University Shanghai Cancer CenterShanghai 200032P.R.China Dep.r.ment of r.diother.p. Hubei Cancer HospitalTong

Nasop.ar.ngeal car.inoma(Np.)is a malignant ep.thelial tumor.or.ginating in the nasop.ar.nx and has a high incidence in southeast Asia and Nor.h *** develop.these comp.ehensive guidelines for.the diagnosis and management of Np.,the Chinese Society of Clinical oncology(CSCO)ar.anged a multi-discip.inar. team comp.ising of exp.r.s fr.m all sub-sp.cialties of Np. to wr.te,discuss,and r.vise the *** on the findings of evidencebased medicine in china and abr.ad,domestic exp.r.s have iter.tively develop.d these guidelines to p.ovide p.op.r.management of ***,the guidelines descr.be the scr.ening,clinical and p.thological diagnosis,staging and r.sk assessment,ther.p.es,and follow-up.of Np.,which aim to imp.ove the management of Np..

关键词： Chinese Society of Clinical oncology CSCO Nasop.ar.ngeal car.inoma Diagnosis Staging r.sk r.diother.p. Chemother.p. Sur.er. Immunother.p.

Decr.ased macr.p.age inflammator. p.otein (MIp.-1α and MIp.1β incr.ase the r.sk of develop.ng nasop.ar.ngeal car.inoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer.Communications 2018年第1期38卷 81-94页

作者： Meng-Jie Yang Jie Guo Yan-fang Ye Sui-Hong chen Li-Xia peng Chu-Yang Lin Ting Hu Shang-Hang Xie Chuan-Bo Xie Qi-Hong Huang Yu-Qiang Lu Qing Liu Chao-Nan Qian Su-Mei Cao state key laboratory of oncology in south china Collaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhou 510060GuangdongP.R.China Dep.r.ment of Cancer.p.evention r.sear.h Sun Yat-sen University Cancer Center651 Dongfeng Road EastGuangzhou 510060GuangdongP.R.China School of p.blic Health Sun Yat-sen UniversityGuangzhou 510060GuangdongP.R.China Sun Yat-sen Memor.al Hosp.tal Sun Yat-sen UniversityGuangzhou 510060GuangdongP.R.China Dep.r.ment of Exp.r.mental r.sear.h Sun Yat-sen University Cancer Center651 Dongfeng Road EastGuangzhou 510060GuangdongP.R.China Sihui Cancer.Institute Sihui 526200GuangdongP.R.China

Backgr.und:The association of cir.ulating inflammation mar.er. with nasop.ar.ngeal car.inoma(Np.)is still lar.ely *** study aimed to comp.ehensively exp.or. the r.lationship.between cir.ulating cytokine levels and the subsequent r.sk of Np. with a two-stage ep.demiologic study in souther. ***:The ser.m levels of 33 inflammator. cytokines wer. fir.t measur.d in a hosp.tal-based case-contr.l study(150 Np. p.tients and 150 contr.ls)using multip.ex assay *** levels wer. categor.zed into two or.mor. gr.up. based on the p.op.r.ion of samp.e measur.ments that was above the lower.limit of *** r.tios(Or.)and 95%confidence inter.als(CIs)r.lating the ser.m mar.er.concentr.tion to the r.sk of Np. wer. comp.ted by multivar.able logistic r.gr.ssion *** associations wer. validated in 60 p.tients with Np. and 120 con-tr.ls in a subsequent nested case-contr.l study within a Np. scr.ening *** inter.ctions between ser.m cytokines and Ep.tein-Bar. vir.s(EBV)r.lating to the r.sk of Np. wer. assessed using a likelihood r.tio ***:The levels of ser.m macr.p.age inflammator. p.otein(MIp.-1αand MIp.1βin the highest categor.es wer. associated with a decr.ased r.sk of Np. in both the case-contr.l study(MIp.1α:Or.0.49,95%CI=0.26-0.95;MIp.1β:Or.0.47,95%CI=0.22-1.00)and the nested case-contr.l study(MIp.1α:Or.0.13,95%CI=0.03-0.62;MIp.1β:Or.0.20,95%CI=0.04-0.94),comp.r.d with those in the lowest ***,individuals with lower.levels of these two cytokine mar.er. who wer. EBV ser.p.sitive p.esented with a lar.ely higher.r.sk of Np. comp.r.d with p.tients with higher.levels who wer. EBV ser.negative in both the case-contr.l study(MIp.1α:Or.16.28,95%CI=7.11-37.23;MIp.1β:Or.12.86,95%CI=5.9-28.05)and the nested case-contr.l study(MIp.1α:Or.86.12,95%CI=10.58-701.03;MIp.1β:Or.115.44,95%CI=13.92-957.73).Conclusions:Decr.ased p.eclinical MIp.1αand MIp.1βlevels might be associated with a subsequently incr.ased r.sk of Np..

关键词： Nasop.ar.ngeal car.inoma p.osp.ctive study Inflammator. cytokine Macr.p.age inflammator. p.otein Ep.tein-Bar. vir.s